In 2011 one of the leading Russian pharmaceutical companies AKRIKHIN expanded its product portfolio with 8 new products. Four of the launched products were new brands and referred to the key pharmacotherapeutic lines of focus for AKRIKHIN: diabetes, tuberculosis, dermatology and gynecology, while the others were extension of the lines of the already existing products. New brands appeared in the company portfolio both as a result of in-house developments of the AKRIKHIN’s R&D Centre, and owing to cooperation with the Russian scientific commonwealth and partnership with foreign companies.
As one of the few Russian companies which have its own Research and Development Centre, AKRIKHIN annually replenishes its portfolio with new products, the whole creation cycle of which – from development to manufacturing – it performs independently. The previous year was memorable for the company due to the launch of two such medicinal products. The first product refers to the therapeutic category of medications for acne treatment, which is new to AKRIKHIN. The second product is intended for treatment of type 2 diabetes mellitus and has been launched within the AKRIKHIN’s strategy of manufacturing socially significant medicinal products.
An original product for treatment of tuberculosis which has no analogues both in Russia and abroad, has appeared in antituberculous line of the company. The launch of the product is a successful case of cooperation of AKRIKHIN with the leading Russian clinicians and foreign partner. In cooperation with the Central Tuberculosis Research Institute of the RAMS AKRIKHIN has developed the medicinal product, and the long-term partner of AKRIKHIN – the Indian manufacturer M.J. Biopharm – has created a tableted pharmaceutical form of the new product based on the data provided by AKRIKHIN. The efficiency and the scientific novelty of the medicinal product have been achieved through a unique combination of components in one medicinal product.
Another example of AKRIKHIN cooperation with the Russian scientific commonwealthwas signing of an agreement with the representatives of the scientific community of the Volgograd State Medical University. As a result of cooperation, AKRIKHIN obtained the rights to the innovative development of a medicinal product for treatment of type 2 diabetes mellitus and will invest in the further technologization and commercialization of the product. This form of partnership complies with the “Strategy of Development of Pharmaceutical Industry of the Russian Federation for the Period up to 2020”, in the implementation of which AKRIKHIN actively participates.
In 2011 AKRIKHIN, as in the previous years, adhered to the policy of diversification, manufacturing drugs under INNs (international nonproprietary names), products sold within state procurement, branded generic products and OTC medicines. Owing to the balanced portfolio AKRIKHIN is present both in the commercial segment and in the state procurement segment. Within the framework of development of the latter line, the company concluded an agreement with one of the largest Indian pharmaceutical developers and manufacturers – Biocon. The result of the cooperation between the parts will be launch on the Russian market of a drug used in transplantology and included in the state programme “7 high-cost nosologies”.
Cooperation with the strategic partner Polpharma also enables AKRIKHIN to expand its portfolio. In 2011 AKRIKHIN launched a product for osteoporosis. The company portfolio previously did not include drugs for osteoporosis. Development and manufacturing of the product is the competence of Polpharma. In its turn, AKRIKHIN will be responsible for marketing and distribution of the product on the Russian market.
About AKRIKHIN:
AKRIKHIN is one of the leading Russian pharmaceutical companies manufacturing high quality medicinal products, and one of the TOP 5 largest local pharmaceutical manufacturers in sales volume on the Russian pharmaceutical market.
AKRIKHIN was established in 1936. The product portfolio of the company includes over 150 medicines of the main pharmaceutical and therapeutic lines: cardiology, neurology, pediatrics, gynecology, dermatology, etc.
AKRIKHIN produces a wide range of socially significant medicines, being one of the largest Russian manufacturers of the products included in the List of Essential Medicines, and medicines against tuberculosis and diabetes.
Since 2007 Polpharma has been a strategic partner of AKRIKHIN on the Russian pharmaceutical market. Strategic partnership is based on close cooperation of the companies in the field of R&D, production and promotion of medicinal products. In 2011 Polpharma strengthened and extended the partnership by purchasing a majority stake in AKRIKHIN.
Based on the 2010 results AKRIKHIN became one of the TOP 3 most authoritative and influential Russian manufacturing pharmaceutical companies in the “Rating of Importance of Subjects of the Russian Pharmaceutical Market" (according to Pharmexpert data).
For additional information, please contact
Julia Zaika, Public Relations Manager
AKRIKHIN
Phone (work): 8 (495) 721-36-97
Mobile: 8 (916) 839-95-71
E-mail: j.zaika@akrikhin.ru